Ciclotizolam

This classification denotes a benzodiazepine with the molecular formula C20H18BrClN4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JK517QTN4Q, chemically known as 2-bromo-4-(o-chlorophenyl)-9-cyclohexyl-6h-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine but generally known as ciclotizolam, which bears US NIH Compound Identifier 71949. European Medicines Agency schedules Ciclotizolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06251MIG. The term CICLOTIZOLAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). CICLOTIZOLAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ciclotizolam under HS 29349990 and SITC 51579. As of Q4 2014, CICLOTIZOLAM remains the US FDA Preferred Term for this commodity. Ciclotizolam bears US NLM identifiers UMLS ID C0055715 and NCI Concept Code C77634. SMILES: BRC1SC2N3C(NNC3CN=C(C2C1)C1C(CL)CCCC1)C1CCCCC1.